REBORNA BIOSCIENCES
Reborna Biosciences provides research and development in the field of genetic diseases. The company develops therapeutic options for area of unmet medical needs in genetic rare disease. The company's technology enables low-molecular compounds to target ribonucleic acid. The company provides new disease-modifying drugs for patients suffering from rare genetic diseases including spinal muscular atrophy.
REBORNA BIOSCIENCES
Industry:
Biotechnology Health Care
Founded:
2018-01-01
Address:
Fujisawa, Kanagawa, Japan
Country:
Japan
Website Url:
http://www.rebornabiosciences.com
Total Employee:
11+
Status:
Active
Contact:
81 466 32 1124
Total Funding:
256 M JPY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Current Employees Featured
Founder
Investors List
Takeda
Takeda investment in Seed Round - Reborna Biosciences
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Seed Round - Reborna Biosciences
Official Site Inspections
http://www.rebornabiosciences.com
- Host name: sv5294.xserver.jp
- IP address: 157.112.183.135
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062
More informations about "Reborna Biosciences"
Reborna Biosciences, Inc.
Contributing to improving healthcare by providing drugs acting on RNA to patients suffering from rare genetic diseases and their families.See details»
株式会社リボルナバイオサイエンス
Save the life of rare disease patients and the parents by RNA binding molecules.See details»
Our Company | 株式会社リボルナバイオサイエンス
RNAの構造化学的および生物科学的特異性に着目し、遺伝性希少疾患に対する治療薬の研究開発を推進するため、2018年株式会社リボルナバイオサイエンスを設立。 同年、当社創業代表取締役（CEO/COO）に就任。 創薬を通じで社会 …See details»
Reborna Biosciences, Inc. | LinkedIn
Reborna Biosciences is a Japan based startup company developing RNA-targeting small molecule drugs for rare genetic diseases. Our proprietary screening method discovers orally …See details»
Drug discovery research collaboration agreement with Reborna ...
Sep 9, 2024 · Under this agreement, both companies will collaborate on drug discovery research targeting intractable genetic rare diseases using Reborna's proprietary RNA-targeting small …See details»
Reborna Bioscience, Inc.: Drug pipelines, Patents, Clinical trials ...
Jun 4, 2023 · Explore Reborna Bioscience, Inc. with its drug pipeline, therapeutic area, technology platform, 1 literature.See details»
Desire to offer drugs that make it possible to be reborn for …
Reborna Biosciences, Inc. (“Reborna”) is a drug discovery venture business carved out from Takeda Pharmaceutical Company Limited. The company name Reborna is a combination of …See details»
Reborna Biosciences - Overview, News & Similar companies
View Reborna Biosciences (www.rebornabiosciences.com) location in Kanagawa, Japan , revenue, industry and description. Find related and similar companies as well as employees …See details»
Reborna Biosciences - Craft
It develops drug discovery technology enabling low-molecular compounds to target RNA. See insights on Reborna Biosciences including office locations, competitors, revenue, financials, …See details»
Reborna Biosciences, Inc. Announces Research Collaboration in …
Reborna Biosciences, Inc. (Kanagawa, Japan; hereinafter, “Reborna”) announced that it has entered into a research collaboration with Biogen (Mass., United States; hereinafter, “Biogen”; …See details»
Reborna Biosciences - Products, Competitors, Financials, …
We will contribute to society by providing new drugs that enable patients suffering from rare genetic diseases and their families to feel that they have been reborn. For more information, …See details»
Reborna Biosciences Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Reborna Biosciences. Use the PitchBook Platform to explore the full profile.See details»
中枢神経系疾患領域における共同研究契約締結のお知らせ : …
Apr 30, 2021 · リボルナ社は、RNAに高い親和性を示す低分子化合物を創出し、RNA機能の正常化により根本治療効果を示す経口型医薬品の創薬研究を行っております。 遺伝性希少疾患 …See details»
Reborna Biosciences, Inc. Enters Research Collaboration with Kissei ...
Sep 9, 2024 · Under this agreement, Reborna will provide its drug discovery platform specializing in the drug discovery of RNA-targeting small molecule drugs and will collaborate the drug …See details»
遺伝性希少疾患の創薬研究を行うリボルナバイオサイエンス、総 …
May 25, 2023 · リボルナバイオサイエンス社は、RNAが持つ幅広い生理機能を調整する低分子化合物をスクリーニングする独自技術を保有する、RNAを標的とした創薬を世界的にリードす …See details»
Reborna Biosciences, Inc. Announces Research Collaboration in …
Apr 30, 2021 · Reborna Biosciences, Inc. Announces Research Collaboration in Central Nervous System DiseasesSee details»
リボルナバイオサイエンス、キッセイ薬品と共同研究契約を締 …
Sep 9, 2024 · 株式会社 リボルナバイオサイエンス（本社：神奈川県藤沢市、代表取締役：富士晃嗣、以下、「リボルナ」）と、キッセイ薬品工業株式会社（本社：長野県松本市、代表取 …See details»
リボルナバイオサイエンス、キッセイ薬品と共同研究契約を締結 …
Sep 9, 2024 · 株式会社 リボルナバイオサイエンス（本部：神奈川県藤沢市、代表取締役：富士晃嗣、以下、「リボルナ」）と、キッセイ薬品工業株式会社（本社：長野県松本市、代表取 …See details»
リボルナバイオサイエンス｜STARTUP DB（スタートアップデー …
遺伝子性希少疾患の領域に特化し、低分子薬の研究開発を手がけるスタートアップ。 この低分子医薬品は、既存の人工的な断片化RNAを利用したスクリーニング法ではなく、RNAが生体 …See details»
Privacy Policy | Reborna Biosciences, Inc.
Reborna Biosciences, Inc. (“us”, “we”, or “our”) operates the http://rebornabiosciences.com/ website (the “Service”). This page informs you of our policies regarding the collection, use, and …See details»